<DOC>
	<DOCNO>NCT01727453</DOCNO>
	<brief_summary>SUMMARY 1.0 . Type Application : Clinical trial compare two treatment term authorize use . 1.1 . Promoter : Institute Research , Hospital de la Santa Creu Sant Pau . Avgda . Sant Antoni M.Claret , 167 . 08025 Barcelona . Tel : ( 34 ) 93 291 9140/93 291 21 73 . 1.2 . Title : Randomized control trial compare treatment oral anticoagulation antagonist vitamin K versus low molecular weight heparin ( Bemiparin ) patient anticoagulation criterion episode gastrointestinal bleeding . 1.3 . Protocol code : HEPACO 1.4 . Principal Investigators : Dr. Candid Villanueva Sanchez . Dr. Jose Mateo Arranz . Contributors : Dr. Alicia Brotons ( Service Digestive Pathology ) , Dr. Angela Puente ( service Digestive Pathology ) , Dr. Isabel Graupera ( Service Digestive Pathology ) Dr. Marina Carrasco ( Hematology Service ) . Hospital de la Santa Creu Sant Pau . Avgda . Sant Antoni Maria Claret , 167 . 08025 Barcelona . Tel : ( 34 ) 93 291 91 39 . Fax : ( 34 ) 93 291 92 78 . E-mail : cvillanueva @ santpau.es . 1.5 . Centers plan trial : Service Gastroenterology Hematology Service Sant Creu Sant Pau , Barcelona . 1.6 . Clinical Research Ethics Committee : Hospital de la Santa Creu Sant Pau . 1.7 . Monitor : Institute Research ( CAIBER ) Hospital de Sant Pau . Avgda . Sant Antoni M.Claret , 167 . 08025 Barcelona . Tel : ( 34 ) 93 291 9140 . 1.8 . Drugs : warfarin , bemiparin . 1.9 . Development stage : Clinical Trial phase IV 1.10 . Main objective : To compare incidence gastrointestinal rebleeding safety oral anticoagulation versus low molecular weight heparin patient acute gastrointestinal bleeding indication anticoagulation . 1.11 . Design : prospective open clinical trial , randomize control . 1.12 . Study disease : acute gastrointestinal bleeding . 1.13 . Primary endpoint valoration : Incidence gastrointestinal bleeding . 1.14 . Study population total number patient : 20 patient require group ( 40 total ) objectify decrease rebleeding rate 45 % alpha error 5 % 10 % beta . 1.15 . Treatment duration : 2 year . 1.16 . Calendar expect completion date : July 2011 - July 2013</brief_summary>
	<brief_title>Compare VKA v LMWH Patients With Anticoagulation Criteria Episode Gastrointestinal Bleeding .</brief_title>
	<detailed_description>4.c . OBJECTIVES : The main objective prospective , randomize study evaluate whether substitution VKA therapy low molecular weight heparin ( bemiparin ) patient episode gastrointestinal bleeding indication anticoagulant therapy , associate decreased incidence recurrent gastrointestinal bleeding . Secondary objective consist follow : - Incidence thromboembolic event - Bleeding location - Severity recurrent episode haemorrhagea - Transfusion requirement - Identification risk factor associate - Mortality 5 . TYPE OF TRIAL AND DESING . This prospective , randomize , control trial , patient gastrointestinal bleed indication anticoagulation randomize two treatment group : Group 1 ( low molecular weight heparin : bemiparin ) , study group : passing bleeding episode , receive low molecular weight heparin ( bemiparin ) anticoagulant dose . Check make measurement anti-factor Xa . Group 2 ( VKA oral anticoagulation : warfarin ) , control group receive VKA anticoagulation bleed episode , regular monitoring measurement prothrombin time ( INR ) . Patients take acenocoumarol bleed episode treat warfarin receive warfarin continue treatment . Treatment control perform measure INR periodically . Randomization perform use seal opaque envelope contain treatment option obtain list random number generate computer . 6 . SELECTION OF SUBJECTS 6.1 CRITERIA FOR INCLUSION AND EXCLUSION : 6.1.1 . Inclusion criterion : patient anticoagulant treatment criterion ( treat acenocoumarol warfarin ) high high risk embolism , acute gastrointestinal bleeding ( high low ) endoscopically untreatable , secondary multiple vascular lesion , diverticular origin unclarified origin ( VGC DC ) exclusion criterion . 6.1.2 . Exclusion criterion . Not included patient one follow criterion : A ) less 18 year old . B ) pregnancy . C ) patient refusal participate study . D ) patient decision take provide active treatment existence clinical situation consider terminal ( severe associate disease evolve ) . E ) Contraindication LMWH ( allergy , heparin induce thrombocytopenia ) . F ) bleed secondary esophageal varix / gastric . G ) associate bleed peptic injury . H ) bleed secondary tumor polyps . ) Presence portal hypertension without cirrhosis . J ) bleed due Mallory-Weiss syndrome . K ) anticoagulation low risk embolic lesion . 6.2 DIAGNOSTIC CRITERIA AND DEFINITIONS : - Acute upper gastrointestinal bleeding : presence hematemesis / melena note medical staff . Any acute gastrointestinal bleeding episode define presence macroscopic sign bleed ( hematemesis , rectal bleeding , hematochezia / melena ) note medical staff . Severe gastrointestinal bleeding define one also present hemodynamic repercusion ( systolic blood pressure &lt; 100 mm Hg heart rate &gt; 100 bpm ) hemoglobin ( Hb ) &lt; 80 g / l decrease Hb &gt; 20 g / l 24 hour . - Upper GI bleed cause peptic ulcer , case urgent endoscopy identify ulcer one follow stigma recent haemorrhage : 1 ) active arterial bleeding jet ooze hemorrhage2 ) non-bleeding visible vessel , 3 ) clot attach , 4 ) indirect sign bleed ( spots deep ulcer ) , 5 ) ulcer without sign evidence blood remain gastric lumen without potentially bleed lesion . - Variceal hemorrhage , case urgent endoscopy identify varices one follow sign bleed : 1 ) active bleed ooze /spurting , 2 ) adherent clot varix platelet clot , recent blood remnant esophagogastric light , 3 ) varix red blood esophagogastric light absence injury complete endoscopic examination . - Upper GI bleed non-variceal neither ulceral origin , case urgent endoscopy identifies lesion ( Mallory-Weiss , Dieulafoy lesion , angiodysplasia ) , active bleeding , non-bleeding visible vessel , adherent clot . - Lower gastrointestinal bleeding , case evidence bleeding ( melena hematochezia ) , urgent endoscopy normal history hematemesis coffee ground vomit . - Rebleeding hemorrhage case present 1 ) new hematemesis recurrence/ persistence fresh melena , associate 2 ) decrease hemoglobin great 20 g / l period le 24 hour , hemodynamic ( TAS &lt; 100 mmHg / heart rate &gt; 100 ppm ) . All case assess new emergency endoscopy confirm recurrence proceed second endoscopic treatment 's necessary . - Very high thromboembolic risk : 1 . Patients first month episode venous thromboembolism . 2 . Presence mitral tricuspid mechanical valve . 3 . Multiple mechanical prosthesis . - High risk thromboembolism , mechanical prosthesis ( except mitral tricuspid high risk ) , atrial fibrillation embolism , valvular atrial fibrillation , venous thromboembolism first three month thrombophilia , atrial fibrillation high risk ( index CHA2DS2- VASC â‰¥ 4 , see table appendix ) . - Low thromboembolic risk : atrial fibrillation ( CHA2DS2-VASC index &lt; 4 ) , venous thromboembolism 6 month . - Mortality : Any death occur course study . We consider attributable bleeding death within 30 day clinical onset bleeding , whatever immediate cause death . 7 . DESCRIPTION OF TREATMENT . Initially , hemodynamic stabilization shall patient accord clinical practice . During bleed episode prophylactic dose heparin administer continuous infusion ( 120 mg / 1-2mg/kg/d ) , start 6 hour administration vitamin K. After 48 hour without clinical sign hemorrhagic activity ( macroscopic blood remnant ) start treatment choice ( thehospital ) . Patients randomized VKA receive warfarin . Patients receive acenocoumarol take warfarin . Patients randomize receive LMWH receive bemiparina ( Hibor ) maintain a-Xa level 0.4-1.0 U / ml . 8 . ASSAY DEVELOPMENT AND EVALUATION OF RESPONSE . 8.A . Parameters evaluate : The following primary secondary parameter evaluate : 1 . Primary variable : incidence upper low gastrointestinal bleeding follow-up period group . Acute gastrointestinal bleeding record , occur , time monitoring period . Is define acute gastrointestinal bleeding episode medical care personnel find presence macroscopic sign bleed ( hematemesis , rectal bleeding , hematochezia / melena ) . Serious Gastrointestinal bleeding define one also present hemodynamic repercussion ( systolic blood pressure &lt; 100 mm Hg heart rate &gt; 100 bpm ) hemoglobin ( Hb ) &lt; 80 g / l decrease Hb &gt; 20 g / l 24 hour . 2 . Secondary variable : 2.1-Mortality : We include deaths period whatever reason immediately . Shall specify date death calculate actuarial probability curve . This consider time 0 , entry first hospital patient go , first bleed sign patient hospitalize . admit first symptom bleeding . 2.2-Severity rebleeding ( TA , FC , low Hb , transfusion requirement ) . 2.3- Association NSAIDs , aspirin antiplatelet agent . 2.5 -treatment complication . It collect adverse event observe follow-up , either initially attributable treatment . Notification serious adverse event unexpected modeled general instruction contain Royal Decree 223/2004 6 February laying requirement conduct clinical drug trial 2.6-Time hospitalization follow-up . 2.7-Number hospitalization follow-up . 2.8-In case rebleeding , report : initial anticoagulation level , endoscopic finding , endoscopic treatment , etc . 8.B.Study development : - Initially evaluation patient anticoagulation criterion ( treat acenocoumarol warfarin ) present upper low gastrointestinal bleeding . All patient submit initial clinical evaluation include history physical examination request blood test ( blood count , biochemistry coagulation ) , ECG , chest radiography abdominal ultrasonography . Anticoagulation correct administration vitamin K ( 10 mg ) analytical control perform 6 hour check reversal anticoagulation . - Then diagnosis therapeutic endoscopy early possible ( least partial correction anticoagulation , INR &lt; 1.6 ) . All patient practise VGC ( also patient suspect low gastrointestinal bleeding , rule completely high origin ) . In patient low gastrointestinal bleeding ( normal VGC ) , conduct VGC VCC . In case source bleed clarify gastroscopy colonoscopy , capsule endoscopy carry , accord result shall practise enteroscopy ( forward/backward ) . Furthermore practised endoscopy , clinical situation case require . In group , suspect rebleeding evaluate endoscopy . - As mention point 7 , bleed episode administer patient prophylactic dose heparin 48 hour without clinical sign hemorrhagic activity divide participation study proceed randomization treatment LMWH vs. warfarin . - Once acute episode resolve , outpatient visit 30th day every 3 month ( complete blood count ) . - Controls anticoagulant therapy use anti-Xa INR hold every four week , except case need change dose , case control frequent .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Gastrointestinal Hemorrhage</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>patient anticoagulant treatment criterion ( treat acenocoumarol warfarin ) high high risk embolism , acute gastrointestinal bleeding ( high low ) endoscopically untreatable , secondary multiple vascular lesion , diverticular origin unclarified origin ( VGC DC ) exclusion criterion . Not included patient one follow criterion : A ) less 18 year old . B ) pregnancy . C ) patient refusal participate study . D ) patient decision take provide active treatment existence clinical situation consider terminal ( severe associate disease evolve ) . E ) Contraindication LMWH ( allergy , heparin induce thrombocytopenia ) . F ) bleed secondary esophageal varix / gastric . G ) associate bleed peptic injury . H ) bleed secondary tumor polyps . ) Presence portal hypertension without cirrhosis . J ) bleed due MalloryWeiss syndrome . K ) anticoagulation low risk embolic lesion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>